Outlook Therapeutics
OTLK
Market cap $40M

1.25 USD

+0.03

2.46%

At close Apr 2, 4:00 PM EDT

After hours

1.25

+0.00

0.00%

1 day

2.46%

5 days

-4.58%

1 month

-11.97%

3 months

-39.32%

6 months

-76.19%

Year to date

-39.32%

1 year

-87.11%

5 years

-89.07%

10 years

-99.82%

About: Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Employees: 23

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,398 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

90,150% more call options, than puts

Call options by funds: $3.61M | Put options by funds: $4K

83% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 12

8% less funds holding

Funds holding: 66 [Q3] → 61 (-5) [Q4]

17.19% less ownership

Funds ownership: 35.44% [Q3] → 18.25% (-17.19%) [Q4]

26% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 19

81% less capital invested

Capital invested by funds: $44.8M [Q3] → $8.59M (-$36.2M) [Q4]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$3

140%

upside

Avg. target

$10.50

740%

upside

High target

$24

1,820%

upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

Ascendiant Capital Edward Woo 30% 1-year accuracy 21 / 71 met price target	1,820%upside $24	Buy Maintained	24 Feb 2025
HC Wainwright & Co. Douglas Tsao 20% 1-year accuracy 35 / 171 met price target	140%upside $3	Buy Maintained	18 Feb 2025
Chardan Capital Daniil Gataulin 26% 1-year accuracy 12 / 47 met price target	140%upside $3	Neutral Maintained	18 Feb 2025
Guggenheim Eddie Hickman 22% 1-year accuracy 2 / 9 met price target	860%upside $12	Buy Reiterated	17 Jan 2025

See Analyst Rankings

Financial journalist opinion

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

ISELIN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced it has re-submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010, an investigational ophthalmic product which, if approved, will be branded as LYTENAVA™ (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD).

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced it participated in the Virtual Investor "Top 5 for ‘25” On-Demand Conference.

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) resubmission on track to meet target of Q1 CY2025 LYTENAVA™ (bevacizumab gamma) on track for first commercial launches in Germany and the United Kingdom (UK) planned for Q2 CY2025 ISELIN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced financial results for the first quarter of fiscal year 2025 and provided a corporate update.

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Dr. Jennifer Kissner, SVP Clinical Development, discusses the 12-week safety and efficacy results for NORSE EIGHT clinical trial

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced Faisal G. Sukhtian has been appointed as Chairman of the Board of Directors, effective immediately. Mr. Sukhtian will assume the role from Randy Thurman, who will remain on the Board as Lead Independent Director.

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

ISELIN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced the presentation of data from NORSE EIGHT at the Hawaiian Eye and Retina 2025 Meeting being held January 18-24, 2025 in Kauai, HI.

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

ISELIN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Lawrence A.

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

On Thursday, Outlook Therapeutics, Inc. OTLK completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular degeneration (wet AMD) patients.

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

ISELIN, N.J., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Outlook Therapeutics, or the Company) (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced it has completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT, the second of two adequate and well controlled clinical trials evaluating ONS-5010 in wet AMD patients. ONS-5010 demonstrated noninferiority to ranibizumab at week 12 in the NORSE EIGHT trial. Based on the completed analysis of the 12-week results, Outlook Therapeutics plans to resubmit the Biologics License Application (BLA) for ONS-5010 in the first quarter of calendar 2025.

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

See News Rankings

Charts implemented using Lightweight Charts™